

## RESEARCH REPORT

# Bloodborne viral infection in Irish injecting drug users

BOBBY P. SMYTH, EAMON KEENAN & JOHN J. O'CONNOR

*The Drug Treatment Centre, Trinity Court, Dublin, Ireland*

### Abstract

**Aims.** In Dublin, harm reduction strategies have greatly expanded since 1990. We sought to determine prevalence of, and factors associated with, hepatitis C (HCV), hepatitis B (HBV) and HIV infection among injecting drug users (IDUs) against this background. **Design.** Cross-sectional survey. **Setting.** Addiction treatment clinic. **Participants.** Seven hundred and thirty-five IDUs tested for antibody to HCV (anti-HCV) between September 1992 and September 1997. **Measurements.** Socio-demographic and use characteristics. Serology tests for anti-HCV, HBV surface antigen (HBsAg) and HIV. **Findings.** A vast majority (89%) commenced injecting since 1990. Prevalence of anti-HCV was 61.8% (453/735), HBsAg was 1.0% (7/729) and of HIV was 1.2% (7/600). Logistic regression analyses indicated that a history of injecting and increased daily drug expenditure were the only independent variables associated with significantly increased risk of HCV. The only characteristic associated with increased prevalence of HIV was a history of injecting prior to 1990 (3.8%, 3/80). HIV prevalence was significantly higher when over 24 years (3.7%, 6/162), when injecting commenced prior to 1990 (6.3%, 4/64) and when injecting 5 years (6.5%, 4/62). **Conclusions.** HIV prevalence has sustained a low level in this population. Interventions which aim to halt transmission of HCV are necessary and will need to target IDUs very early in their injecting careers and also those at risk of commencing to inject.

### Introduction

World-wide, injecting drug users (IDUs) represent a high risk group for bloodborne viral infections, including HIV,<sup>1</sup> hepatitis B (HBV)<sup>2</sup> and hepatitis C (HCV).<sup>3</sup> Harm reduction strategies<sup>4</sup> have been advocated in order to prevent spread of bloodborne viral infection and many believe that these approaches have contributed to a reduced incidence of HIV.<sup>5,6</sup> There is only limited evidence that needle exchange attendance is associated with a reduction in HCV and HBV infections.<sup>7</sup> A recent study of the incidence of HCV infection among IDUs failed to find a

reduction in those who attended for methadone maintenance therapy.<sup>8</sup> There is a concern that current approaches may not be adequate to reduce the occurrence of unsafe injecting practices to a sufficiently low level to ensure a low prevalence of HCV in populations of IDUs where prevalence of HCV is already high.<sup>3</sup> It is possible for harm reduction programmes to appear effective by minimizing new cases of HIV while having little impact on HCV.

In Dublin harm reduction strategies have been in existence since 1989. These services have been vastly expanded in the 1990s. The number

---

Correspondence to: Dr Bobby Smyth, Department of Addiction Research, AIDS/Drugs Service, Clonorchard Hospital, Dublin 10, Ireland.

Submitted 31st December 1997; initial review completed 10th March 1998; final version accepted 29th March 1998.

0965-2140/98/111649-08 \$9.50 © Society for the Study of Addiction to Alcohol and Other Drugs

Carfax Publishing Limited

official needle exchange centres in the city has grown from one to 12 since 1990, the number of community outreach workers has trebled in the same period and access to methadone treatment has improved with the addition of four new addiction treatment centres and 12 satellite clinics. Trinity Court is the largest and longest established treatment centre in Dublin. Referrals are accepted from all areas of the city. New attenders tend to present early in their injecting careers. Patients with a history of injecting are encouraged to agree to screening tests for HIV, HBV and HCV. We sought to measure the prevalences of these viral infections against the background of the expanding harm reduction programme.

### Methods

Since September 1992, data have been recorded on an ongoing basis on all new attenders who were IDUs and tested for anti-HCV. When available, the results of screening tests for HBV and HIV were included. A doctor (BS), who was blind to the test results, obtained socio-demographic details and some drug use characteristics from the medical notes of the initial assessment interview. The variables chosen for inclusion were those found to be most frequently and reliably recorded in a pilot study prior to commencement of this project. Data was incomplete in only 28 cases (3.8%). We report here the results of the first 5 years of this data collection.

### Viral markers

Prior to July 1993, the screening test for HCV was a second generation enzyme linked immunosorbant assay (EIA) for anti-HCV (Ortho Diagnostics, Amersham, Buckinghamshire, UK). Subsequently, the third generation EIA was used. All positive results were confirmed with an additional EIA. A recombinant immunoblot assay was used in situations where the two EIA gave contradictory results. The screening test for HBV was an EIA for hepatitis B surface antigen. The initial screen for HIV was with two EIA tests for antibody to HIV. Positive tests were confirmed with the Western blot assay.

### Statistical methods

Confidence intervals were calculated by using exact methods for proportions. Analytical tech-

niques included Pearson's  $\chi^2$  test and Fisher's exact test statistic to determine the significance of associations for categorical variables. For ordered categorical variables the Mantel-Haenszel  $\chi^2$  test for linear trend was used. Odds ratios and their 95% confidence intervals were used to describe the relationship between subject characteristics and serology results. Student's *t*-test was used for difference in the means of continuous variables; the Mann-Whitney *U*-test was performed when the distribution of a continuous variable was skewed. For HCV, multivariate analyses were performed using logistic regression and variables found to be significant on univariate analyses were entered into the regression equation.<sup>9</sup>

### Results

Of 733 attenders, 453 were anti-HCV positive (61.8%, 95% confidence interval 58.3–65.3%). Table 1 presents the relationship between anti-HCV and the socio-demographic and drug use variables. Older age, longer history of injecting, commencement of injecting prior to 1990 and daily drug expenditure of over Ir£65 were each significantly associated with increased risk. There was a tendency for unemployed attenders to be more likely to be anti-HCV positive (NS) and a similar tendency was observed in those who were in a sexual relationship with another IDU (NS). Figure 1 depicts the association between duration of injecting and HCV status. Multivariate analysis indicated that only longer history of injecting and daily drug expenditure of over £65 were independently associated with increased risk of HCV. The prevalence of HBsAg was 1.0% (7/729 [95% confidence interval 0.3–1.7%]). The only independent variable significantly associated with increased risk of HBV was a history of injecting prior to 1990 (see Table 2: due to the small number testing positive, categories were compressed). Those testing positive for HBsAg had longer injecting histories but this was not significant (medians, 45.0 months vs. 15.9 months, Mann-Whitney *U*-test,  $p = 0.08$ ).

The prevalence of HIV was 1.2% (7/600 [95% confidence interval 0.3–2.0%]). An injecting history of over 5 years, commencement of injecting prior to 1990 and age over 24 were each significantly associated with increased proportion testing positive for HIV (see Table 2). No test




Figure 1. Prevalences of anti-HCV, hepatitis B surface antigen and HIV in serial cohorts with increasing time since onset of injecting (1-4 months, 5-8 months, 9-12 months, 13-24 months, 25-60 months and over 60 months, y-axis coordinate equates to the mean period since onset of injecting for each cohort): results from new attenders to the Trinity Court Drug Treatment Centre, Dublin, between September 1992 and September 1997.

result was available in 133 cases and two results were indeterminate. Those reporting MST as their primary drug were under-represented in the group tested for HIV (Pearson's  $\chi^2$  test,  $p=0.04$ ). No other independent variable was associated with uptake of HIV testing.

There was no significant association between any combination of the three viral markers.

#### Discussion

There are four possible areas of methodological concern in this study. First, no data are presented on the reported frequency of unsafe injecting practices. Such practices are best examined via a standardized and detailed structured interview and possibly requiring an interviewer independent of treatment services.<sup>10,11</sup> Due to the long-term nature of this ongoing study, there was no practical way of overcoming these obstacles and we therefore decided that no data on this area would be better than data of questionable reliability. Secondly, the daily drug expenditure was taken as a crude measure of daily drug use and injecting frequency. However, the 'street' price of heroin reduced by nearly

50% over the study period, falling to Ir£20 per 'quarter gram' in 1996-97. A third possible source of concern could be the change in the HCV screening test from a second generation to a third generation EIA early in the study period. Although the enhanced specificity of the third generation test substantially increases the positive predictive value of screening in very low prevalence populations such as blood donors, the change in positive predictive value in the high prevalence population studied here would be minimal.<sup>12,13</sup> Repeat examination of the data excluding those screened with the second generation test did not reveal any significant alteration in the reported findings on either univariate or multivariate analysis. Finally, there may be concern regarding possible selection bias in the HIV tested group as a substantial minority (18%) of the study group were not screened for HIV. Importantly, those not tested did not differ significantly in terms of any of the variables demonstrated to be associated with bloodborne infection.

The variables significantly associated with increased risk of HCV are also those which are potentially associated with increased

8. CROFTS, N., NIGRO, L., OMAN, K., STEVENSON, E. & SHERMAN, J. (1997) Methadone maintenance and hepatitis C virus infection among injecting drug users, *Addiction*, 92, 999-1005.
9. DALY, L. E., BOURKE, J. B. & MCGILVRAY, J. (1991) *Interpretation and Uses of Medical Statistics* (Oxford, UK, Blackwell Scientific Publications).
10. STIMSON, G. V., JONES, S., CHALMERS, C. & SULLIVAN, D. (1998) A short questionnaire (IRQ) to assess injecting risk behaviour, *Addiction*, 93, 337-347.
11. MORRISON, C. S., MCCUSKER, J., STODDARD, A. S. & BIGELOW, C. (1995) The validity of behavioral data reported by injection drug users on a clinical risk assessment, *International Journal of the Addictions*, 30, 889-899.
12. DE LAMBALLERIE, X. (1996) Serological and molecular biology screening techniques for HCV infection, *Nephrology, Dialysis, Transplantation*, 11 (suppl. 4), 9-11.
13. SCHREIBER, G. B., BUSCH, M. P., KLEINMAN, S. H. & KORELITZ, J. J. (1996) The risk of transfusion transmitted viral infections. The Retrovirus Epidemiology Donor Study, *New England Journal of Medicine*, 334, 1685-1690.
14. MCKEGANEY, N., ABEL, M., TAYLOR, A., FRISCHER, M., GOLDBERG, D. & GREEN, S. (1995) The preparedness to share injecting equipment: an analysis using vignettes, *Addiction*, 90, 1253-1260.
15. DORMAN, A., KEENAN, E., SHUTTLE, C., MERRY, J. & O'CONNOR, J. J. (1997) HIV risk behaviour in Irish intravenous drug misusers, *Irish Journal of Medical Science*, 166, 235-238.
16. GARFEIN, R. S., VLAHOV, D., GALIA, N., DOHERTY, M. C. & NELSON, K. E. (1996) Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphocyte viruses, *American Journal of Public Health*, 86, 655-661.
17. JOHNSON, Z., O'CONNOR, M., POMEROY, L. et al., (1994) Prevalence of HIV and associated risk behaviour in attendees at a Dublin needle exchange, *Addiction*, 89, 603-607.
18. FOSTER, G. R., GOLDIN, R. D., MAIN, J., MURRAY-LYON, L., HARGREAVES, S. & THOMAS, H. C. (1997) Management of chronic hepatitis C: clinical audit of biopsy based management algorithm, *British Medical Journal*, 315, 453-458.
19. WODAK, A. (1997) Hepatitis C: waiting for the grim reaper, *Medical Journal of Australia*, 166, 284-285.
20. STRANG, J., GRIFFITHS, P. & GOSSOP, M. (1997) Heroin smoking by 'chasing the dragon': origins and history, *Addiction*, 92, 673-683.

**Table 2.** General characteristics and injecting drug use behaviours of new attenders to the Trinity Court Drug Treatment Centre, Dublin, between September 1992 and September 1997, by HIV and hepatitis B surface antigen prevalences.

	HIV		Hepatitis B sAg	
	Proportion testing positive (%)	Fisher's test, † <i>p</i> value	Proportion testing positive (%)	Fisher's test, † <i>p</i> value
Total	7/600 <sup>a</sup> (1.2)		7/729 <sup>b</sup> (1.0)	
Age (years)				
24 or less	1/438 (0.2)		4/533 (0.8)	
25 or over	6/162 (3.7)	0.002	3/196 (1.5)	0.39
Gender				
Male	5/432 (1.2)		6/525 (1.1)	
Female	2/168 (1.2)	1.0	1/204 (0.05)	0.68
Employment				
Unemployed	6/542 (1.1)		6/655 (0.9)	
Working (or at school)	1/58 (1.7)	0.51	1/74 (1.4)	0.53
Current sexual relationship				
No partner/partner not injecting	4/402 (1.0)		5/491 (1.0)	
Partner injecting	2/175 (1.1)	1.0	2/212 (0.9)	1.0
Time since 1st injecting, years				
Less than 5 years	3/538 (0.6)		5/654 (0.8)	
5 years or more	4/62 (6.5)	0.003	2/75 (2.7)	0.16
Principal drug injected				
Heroin	7/457 (1.5)		5/541 (0.9)	
Other	0/143 (0)	0.20	2/188 (1.1)	1.0
Age 1st injected (years)				
24 or less	5/525 (1.0)		7/640 (1.1)	
25 or more	2/75 (2.7)	0.22	0/89 (0)	1.0
When injecting commenced				
Pre-1990	4/64 (6.3)		3/80 (3.8)	
Post-1990	3/536 (0.6)	0.003	4/649 (0.6)	0.03
Daily drug expenditure				
Ir£65 or less	3/405 (0.7)		3/481 (0.6)	
More than Ir£65	4/194 (2.1)	0.22	4/246 (1.6)	0.23
Year of testing				
1992-94	4/267 (1.5)		5/342 (1.5)	
1995-97	3/333 (0.9)	0.71	2/387 (0.5)	0.26

<sup>a</sup>No HIV test was performed in 133 cases and the result was indeterminate in two cases. <sup>b</sup>No HBsAg test was conducted in six cases.

life-time injecting episodes. Each injecting episode presents a possible scenario where the sharing of injecting equipment may occur.<sup>14</sup> Research conducted in Trinity Court in 1993 found that 56% of IDUs had shared syringes in the preceding 6 months.<sup>15</sup> The prevalence of HCV in those who commenced injecting in this decade, and thereby had access to expanded harm

reduction strategies, remains high at 58.9%. Although this proportion is significantly lower compared to those who began injecting earlier, multivariate analysis indicates that this finding is due to the confounding effect of shorter injecting history and could therefore not be used to support a conclusion that there has been any reduction in unsafe injecting practices. Figure 1

demonstrates the rapid acquisition of HCV after initiation into injecting. This supports the view expressed by Garfein and colleagues that those seeking to prevent spread of HCV among IDUs have a very narrow window of opportunity in which to do so.<sup>10</sup>

The small proportion of IDUs demonstrating current infectivity for HBV indicates that the pool from which HBV infection can arise is very much smaller than the corresponding pool of HCV infection. Also, the fact that most services dealing with IDUs in Dublin, including prisons, have a policy of actively encouraging the uptake of HBV vaccination may be contributing to its low prevalence. Screening for the antibody markers of HBV would have yielded valuable additional information about the proportion of IDUs with previous exposure to this virus.<sup>2</sup> Unfortunately, such tests were not routinely performed.

Johnson has reported HIV prevalence of 14.8% among IDUs attending a Dublin needle exchange in 1991.<sup>17</sup> The prevalence detected among our study group is very much lower (1.2%). This reduction is striking but it must be noted that the group studied here are younger and injecting histories are shorter than the previously studied group. Our data demonstrates a sustained low prevalence of HIV among new attenders to our treatment service. In their review of cities with sustained low prevalence of HIV among IDUs, Des Jarlais and colleagues have described three features which they considered important.<sup>5</sup> These are the early adoption of harm reduction strategies, utilization of community outreach and ensuring access to sterile injecting equipment. Dublin has indeed embraced these approaches. Nevertheless, the observed reduction in prevalence of HIV infection in those who commenced injecting in this decade may simply reflect their shorter injecting history. Ongoing monitoring of HIV test results over the coming years may clarify this issue and will provide an area for further research.

Hepatitis C is associated with substantial morbidity and mortality.<sup>18</sup> Current harm reduction strategies appear ineffective in protecting IDUs from this infection.<sup>8,19</sup> Proposed novel adaptations to these strategies will attempt to educate IDU (or potential IDUs) during, or before, the narrow 'window of opportunity' and may in time prove beneficial.<sup>16</sup> In Europe, increasing numbers of drug misusers are being introduced to heroin through 'chasing the dragon' before poss-

ibly progressing on to injecting.<sup>20</sup> Education of this group regarding safe injecting and the risk of HCV should be considered. Overall, we believe that in Dublin, among IDUs who commenced injecting in this decade, our data support the view that hepatitis C will create a larger health burden than either hepatitis B or HIV/AIDS. Harm reduction approaches should adapt to this change in need. Hence, while the low prevalence of HIV must be welcomed, any decision by policy makers that funds could now be diverted away from harm reduction would be very premature.

#### Acknowledgements

The authors wish to acknowledge the contribution of the staff at the Virus Reference Laboratory, Dublin, where all blood tests were analysed. We also wish to thank Drs Joe Barry, Bob McDonald and Zachary Johnson for their advice and criticism in the preparation of this manuscript. Finally, we wish to express our gratitude to Siobhan Fisher for her administrative support and to Louise McAuley and Debbie Smullen for assistance with data management.

#### References

1. WHO COLLABORATIVE STUDY GROUP (1993) An international comparative study of HIV prevalence and risk behaviour among drug injectors in 13 cities, *Bulletin on Narcotics*, XLV, 19-46.
2. LEVINE, O. S., VLAHOV, D. & NELSON, K. E. (1994) Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors and viral interactions, *Epidemiologic Reviews*, 16, 418-436.
3. WODAK, A. & CROFTS, N. (1996) Once more unto the breach: controlling hepatitis C in injecting drug users, *Addiction*, 91, 181-184.
4. BRETTELE, R. P. (1991) HIV and harm reduction for injecting drug users, *AIDS*, 5, 125-136.
5. DES JARLAIS, D. C., HAGAN, H., FRIEDMANN, S. R. *et al.* (1995) Maintaining low HIV seroprevalence in populations of injecting drug users, *Journal of the American Medical Association*, 274, 1226-1231.
6. STIMSON, G. V. (1996) Has the United Kingdom averted an epidemic of HIV-1 infection among drug injectors? *Addiction*, 91, 1085-1088.
7. HAGAN, H., DES JARLAIS, D. C., FRIEDMAN, S. R., PURCHASE, D. & ALTER, M. J. (1995) Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program, *American Journal of Public Health*, 85, 1531-1537.

When injecting commenced	n (%)	OR (95% CI)	p-value
Pre-1990	81 (11)	0.85 (0.51-1.41)	0.69*
Post-1990	652 (89)	1.0	
Daily drug expenditure <sup>e</sup>			
Less than Ir£35	169 (23)	0.25 (0.13-0.47)	<0.001*
Ir£36-Ir£65	314 (43)	1.0	
More than Ir£65	248 (34)	1.01 (0.68-1.50)	1.0
Year of test			
1993 <sup>d</sup>	160 (23)	1.71 (1.12-2.63)	0.006*
1994	177 (24)	1.0	
1995	152 (21)	0.75 (0.47-1.19)	
1996	118 (16)	0.82 (0.50-1.33)	
1997	116 (16)	0.53 (0.32-0.88)	0.11†
		0.78 (0.46-1.32)	

†Mantel-Haenszel  $\chi^2$  test for trend. \* Pearson test  $\chi^2$ . <sup>a</sup>Status of partner unknown in 26 cases. <sup>b</sup>Numbers using benzodiazepines too low to allow valid calculation of 95% confidence interval for odds ratio. <sup>c</sup>Daily drug expenditure unknown in two cases. <sup>d</sup>Includes 20 patients tested between September 1992 and December 1992.

Table 1. Distribution of general characteristics and injecting drug use behaviours of new attenders to the Trinity Court Drug Treatment Centre, Dublin, between September 1992 and September 1997, by anti-HCV prevalence. Univariate and logistic regression analysis of associations

	Number (%)	HCV prevalence (%)	Univariate analysis		Multivariate analysis	
			Odds ratio (95% confidence interval)	p value	Odds ratio (95% confidence interval)	p value
Total	733	61.8				
Age, years						
18 or less	126 (17)	53.2	1.0		1.0	
19-21	249 (34)	57.0	1.17 (0.74-1.84)		0.70 (0.43-1.13)	0.14
22-24	160 (22)	67.5	1.83 (1.10-3.05)		1.14 (0.67-1.94)	0.64
25 or more	198 (27)	68.7	1.93 (1.19-3.15)	0.001†	0.80 (0.44-1.33)	0.35
Gender						
Male	529 (72)	61.4	1.0			
Female	204 (28)	62.7	1.06 (0.76-1.47)	0.74*		
Employment						
Working (or at school)	75 (10)	52.0	1.0			
Unemployed	658 (90)	62.9	1.57 (0.97-2.53)	0.07*		
Current sexual relationship <sup>a</sup>						
No partner/ non-injecting partner	493 (70)	60.0	1.0			
Partner injects	214 (30)	66.4	1.31 (0.93-1.86)	0.11*		
Time since onset of injecting, months						
1-4	109 (15)	26.6	1.0		1.0	
5-8	108 (15)	48.1	2.56 (1.40-4.71)		2.53 (1.42-4.52)	0.002
9-12	99 (14)	66.7	5.52 (2.92-10.49)		5.95 (3.24-10.92)	<0.001
13-24	183 (25)	64.5	5.01 (2.88-8.74)		5.09 (2.97-8.71)	<0.001
25-60	158 (22)	77.8	9.69 (5.30-17.84)		10.73 (5.88-19.57)	<0.001
> 60	76 (10)	85.5	16.30 (7.14-38.02)	<0.001†	16.64 (4.46-62.11)	<0.001
Principal drug injected						
Heroin	544 (74)	61.4	1.0			
Morphine sulphate (MST)	113 (15)	62.8	1.06 (0.69-1.65)			
Both heroin & MST	69 (9)	65.2	1.18 (0.68-2.06)			
Benzodiazepine <sup>b</sup>	7 (1)	42.9	0.47	0.68*		